Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study

Summary: STRIDE-II presents treatment targets for both adult and pediatric IBD, including long-term and short-term goals. These targets cover aspects such as clinical response, endoscopic healing, quality of life, and growth, providing guidance for improving patient outcomes.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis

Siddharth Singh et al.

Summary: This study conducted a systematic review and network meta-analysis to evaluate the comparative efficacy and safety of biologics in patients with moderate-to-severe Crohn's disease. The results suggest that infliximab with azathioprine or adalimumab may be preferred as a first-line therapy, while adalimumab (after infliximab loss of response) or risankizumab may be preferred as a second-line therapy for induction of clinical remission in patients.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Dermatology

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up

K. A. Papp et al.

Summary: The study evaluated the long-term efficacy and safety of risankizumab for psoriasis treatment, with results showing high and durable efficacy over 172 weeks and low rates of adverse events.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

Siddharth Singh et al.

Summary: The global incidence and prevalence of Crohn's disease (CD) is increasing, with patients at high risk for complications, surgery, and hospitalization. Optimal management of moderate to severe CD often requires immunomodulators and/or biologic therapies, but guidelines on comparative efficacy are limited, leading to variability in practice.

GASTROENTEROLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology